Dr Martens investor calls for strategic review

R0007841

In a letter seen by Reuters, the New York based investment firm said the “stalled earnings growth and sharp share price drop” of 83% since its public listing in 2021 have “decoupled its valuation from its intrinsic value”.

 

Already have an account?

Want to read more?

Register for LIMITED guest access

Register now

Get premium access

£5 A MONTH for 3 months

Subscribe now